Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-15
2006-08-15
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S469000
Reexamination Certificate
active
07091234
ABSTRACT:
This invention relates to compounds which are agonists of the progesterone receptor which have the general structure:wherein:R1, R2, R3, R4, R5and Q1are as defined herein, or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds to induce contraception or treat progesterone-related carcinomas and adenocarcinomas.
REFERENCES:
patent: 3635964 (1972-01-01), Skorcz
patent: 3917592 (1975-11-01), Kobzina
patent: 4093730 (1978-06-01), Butti
patent: 4440785 (1984-04-01), Walsh
patent: 4617302 (1986-10-01), Robertson
patent: 4666913 (1987-05-01), Kubla
patent: 4670566 (1987-06-01), Walsh
patent: 4721721 (1988-01-01), Kuhla
patent: 4822794 (1989-04-01), Spada
patent: 4831027 (1989-05-01), Narr
patent: 4853473 (1989-08-01), Fischer
patent: 4933336 (1990-06-01), Martin
patent: 5007952 (1991-04-01), Kume
patent: 5171851 (1992-12-01), Kim
patent: 5182282 (1993-01-01), Clemence
patent: 5300655 (1994-04-01), Ehrgott
patent: 5414088 (1995-05-01), von der Saal
patent: 5447928 (1995-09-01), Williams
patent: 5453516 (1995-09-01), Fischer
patent: 5475020 (1995-12-01), Johnson
patent: 5521166 (1996-05-01), Grubb
patent: 5552412 (1996-09-01), Cameron
patent: 5565483 (1996-10-01), Hewawasam
patent: 5576330 (1996-11-01), Buzzetti
patent: 5659046 (1997-08-01), Kameswaran
patent: 5681817 (1997-10-01), Hodgen
patent: 5688808 (1997-11-01), Jones
patent: 5688810 (1997-11-01), Jones
patent: 5693646 (1997-12-01), Jones
patent: 5693647 (1997-12-01), Jones
patent: 5696127 (1997-12-01), Jones
patent: 5696130 (1997-12-01), Jones
patent: 5696133 (1997-12-01), Jones
patent: 5719136 (1998-02-01), Chwalisz
patent: 5733902 (1998-03-01), Schneider
patent: 5808139 (1998-09-01), Pathirana
patent: 5874430 (1999-02-01), Christ
patent: 6077840 (2000-06-01), Kurihara
patent: 6153622 (2000-11-01), Cameron
patent: 6204286 (2001-03-01), Cameron
patent: 6306851 (2001-10-01), Santilli
patent: 6319912 (2001-11-01), Grubb
patent: 6329416 (2001-12-01), Grubb
patent: 6339098 (2002-01-01), Collins
patent: 6355648 (2002-03-01), Fensome
patent: 6358947 (2002-03-01), Zhi
patent: 6358948 (2002-03-01), Zhang
patent: 6369056 (2002-04-01), Zhang
patent: 6380178 (2002-04-01), Grubb
patent: 6380235 (2002-04-01), Zhang
patent: 6391907 (2002-05-01), Fensome
patent: 6396056 (2002-05-01), Lord
patent: 6399593 (2002-06-01), Grubb
patent: 6407101 (2002-06-01), Collins
patent: 6417214 (2002-07-01), Ullrich
patent: 6423699 (2002-07-01), Grubb
patent: 6436929 (2002-08-01), Zhang
patent: 6441019 (2002-08-01), Santilli
patent: 6441193 (2002-08-01), Cameron
patent: 6444668 (2002-09-01), Grubb
patent: 6462032 (2002-10-01), Grubb
patent: 6498154 (2002-12-01), Grubb
patent: 6503939 (2003-01-01), Grubb
patent: 6509334 (2003-01-01), Zhang
patent: 6521657 (2003-02-01), Fensome
patent: 6544970 (2003-04-01), Grubb
patent: 6562857 (2003-05-01), Collins
patent: 6566358 (2003-05-01), Zhang
patent: 6566372 (2003-05-01), Zhi
patent: 6583145 (2003-06-01), Fensome
patent: 6608068 (2003-08-01), Fensome
patent: 6693103 (2004-02-01), Zhang
patent: 6713478 (2004-03-01), Zhang
patent: 6759408 (2004-07-01), Grubb
patent: 6794373 (2004-09-01), Grubb
patent: 6835744 (2004-12-01), Ullrich
patent: 6841568 (2005-01-01), Fensome
patent: 2001/0025051 (2001-09-01), Cameron
patent: 2002/0111355 (2002-08-01), Zhang
patent: 2002/0115853 (2002-08-01), Zhang
patent: 2002/0169198 (2002-11-01), Fensome
patent: 2003/0008909 (2003-01-01), Ullrich
patent: 2003/0092711 (2003-05-01), Zhang
patent: 2003/0130505 (2003-07-01), Zhi
patent: 2003/0158182 (2003-08-01), Collins
patent: 2003/0220388 (2003-11-01), Fensome
patent: 2004/0002535 (2004-01-01), Fensome
patent: 2004/0006060 (2004-01-01), Fensome
patent: 2004/0006122 (2004-01-01), Fensome
patent: 2004/0014798 (2004-01-01), Fensome
patent: 2004/0186101 (2004-09-01), Zhang
patent: 1118784 (1961-12-01), None
patent: 3633861 (1988-04-01), None
patent: 4330234 (1995-03-01), None
patent: 4344463 (1995-06-01), None
patent: 022317 (1981-01-01), None
patent: 208510 (1987-01-01), None
patent: 311135 (1989-04-01), None
patent: 385850 (1990-09-01), None
patent: 483077 (1991-09-01), None
patent: 454330 (1991-10-01), None
patent: 535529 (1992-09-01), None
patent: 510235 (1992-10-01), None
patent: 947507 (1999-10-01), None
patent: 978279 (2000-02-01), None
patent: 63112584 (1988-05-01), None
patent: 2067576 (1996-10-01), None
patent: 2073671 (1997-02-01), None
patent: 95121739 (1998-02-01), None
patent: 96111002 (1998-09-01), None
patent: WO-86/03749 (1986-07-01), None
patent: WO-91/04974 (1991-04-01), None
patent: WO-91/06545 (1991-05-01), None
patent: WO-93/12085 (1993-06-01), None
patent: WO-94/14434 (1994-07-01), None
patent: WO-94/29272 (1994-12-01), None
patent: WO-95/11013 (1995-04-01), None
patent: WO-95/20972 (1995-08-01), None
patent: WO-95/33746 (1995-12-01), None
patent: WO-96/15794 (1996-05-01), None
patent: WO-96/19458 (1996-06-01), None
patent: WO-96/19997 (1996-07-01), None
patent: WO-97/13767 (1997-04-01), None
patent: WO-97/49407 (1997-12-01), None
patent: WO-98/14436 (1998-04-01), None
patent: WO-98/27059 (1998-06-01), None
patent: WO-98/55116 (1998-12-01), None
patent: WO-99/10325 (1999-03-01), None
patent: WO-99/11264 (1999-03-01), None
patent: WO-99/15500 (1999-04-01), None
patent: WO-99/44608 (1999-09-01), None
patent: WO-01/15108 (2001-03-01), None
Lazarenko et al., Khimiya Geterotsiklicheskikh soedinenii (1982), vol. 10, pp. 1363-1366.
Lazarenko et al., Khimiya Geterotsiklicheskikh soedinenii (1976), vol. 4, pp. 497-499.
Andreani et al., “Potential antitumor agents XVII(1). Cytotoxic agents from indole derivatives and their intermediates”,Acta. Pharm. Nord. 1990 2(6):407-414.
Arndt et al., “New Heterocycle substituted Benzo-Fused Azine and Azole Derivatives—Useful as Selective Herbicides for Pre or Post-Emergence Application”, Oct. 10, 1988 Derwent WPI Abstract EP 311135.
Barengolts et al., “Progesterone antagonist RU486 has bone-sparing effects in ovariectomized rats”,BoneJul. 1995 17(1):21-25.
Brumagniez et al., “Benzimidazole and Azabenzimidazole(s)—Having Cardiotonic, Vasodilating, Anti-Hypertensive, Anti-Aggregation, and Anti-Ulcer Activity”, Feb. 27, 1990 Derwent WPI Abstract EP 385850.
Buzzetti et al., “3-(Bicyclylmethylene)oxindole antiangiogenic agents”, Nov. 19, 1996 Abstract of US Patent No. 5,576,330.
Canonne et al., “Spirocyclization of 1-(o-Aminophenyl)cycloalkanols and 1-(2′-Amino-3′-pyridinyl)cycloalkanols”,J. Heterocyclic Chem. Jan.-Feb. 1989 26:113.
Chen et al., “Synthesis and SAR of a novel series of spirobenzothlzaepine derivatives with antiprogestin activity”, POI-37, 16thInt. Cong. Het. Chem., Montana 1997.
Chiarino et al., “2,1-Benzisothiazoline 2,2-Dioxide and derivatives”,J. Heterocycl. Chem. Nov.-Dec. 1986 23(6):1645-1649.
Chwalisz et al. “Contraceptive Pack for Implantation Inhibition—Contains Competitive Progesterone Antagonist and Gestagen for Sequential Oral Administration.”, Jun. 29, 1995 Derwent WPI Abstract DE 4,344,463.
Chwalisz et al. “Female Contraceptive Method Comprises Gestation Treatment with Intermittent Progesterone Antagonist Administration.”, Mar. 9, 1995 Derwent WPI Abstract DE 4,330,234.
Clemence et al., “New 4-(amino-alkoxy-phenyl-methyl)1H-indole derivatives”, Oct. 10, 1996 Abstract of Russian Patent No. 2067576.
Combs et al., “Heteroatom analogues of bemoradan: Chemistry and cardiotonic activity og 1,4-Benzothiazinylpyridazinones”,J. Med. Chem. Jan. 1992 35:172-176.
Combs et al., “Nonsteroidal progesterone receptor ligands. 2. High-affinity ligands with selectivity for bone cell progesterone receptors”,J. Med. Chem. Dec. 8, 1995 38:4880.
Derwent WPI Abstract, “New Imidazo-Pyridine Derivatives—Useful as Platelet Agglutination Inhibitor, Antiallergic, Antiinflammatory Sedative, Cardiac, and Cardiovascular Vasodilators”, May 17, 1988 JP 63112584.
Edwards et al., “5-Aryl-1,2-Dihydro-5H-Chromeno[3,4-f]Quinolines as p
Edwards James P.
Fensome Andrew
Jones Todd K.
Koko Marci C.
Melenski Edward G.
Howson and Howson
Wyeth
LandOfFree
Thio-oxindole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thio-oxindole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thio-oxindole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3615303